<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607111414022</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607111414022</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Effect of Early Enteral Nutrition on Hyperthermic Intraoperative Intraperitoneal Chemotherapy–Induced Mucosal Permeability Following Gastrectomy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Gang</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414022">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gu</surname><given-names>Rongmin</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414022">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wen</surname><given-names>Xu</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414022">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wei</surname><given-names>Da</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414022">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ming</surname><given-names>Xuezhi</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414022">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Chen</surname><given-names>Huanqiu</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414022">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607111414022"><label>1</label>Jiangsu Cancer Hospital, Nanjing, Jiangsu, China</aff>
<author-notes>
<corresp id="corresp1-0148607111414022">Dr Huanqiu Chen, Jiangsu Cancer Hospital, Baiziting 42, Xuanwu Distinct, Nanjing, Jiangsu, China 210009; e-mail: <email>gang_lee@medmail.com.cn</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>2</issue>
<fpage>213</fpage>
<lpage>218</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>11</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>1</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 The American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Aim</italic>: To investigate (1) the effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) on intestinal permeability of patients with advanced gastric cancer and (2) the protective effect of postoperative enteral nutrition (EN) on patients. <italic>Methods</italic>: &gt;All patients were divided randomly into 3 groups: the EN group, treated with EN during postoperative period; the EN+HIIC group, treated with HIIC and postoperative EN; and the PN+HIIC group, treated with HIIC and postoperative parenteral nutrition. The lactulose/mannitol (L/M) ratio was used to evaluate the permeability of intestinal mucous. <italic>Results</italic>: Compared with the ratio of L/M on the day before operation (POD-1), the ratio of L/M on POD+3 increased significantly in all 3 groups (<italic>P</italic> &lt; .0001) and then decreased gradually. The L/M ratio of the EN and EN+HIIC groups recovered to the baseline on POD+12. In contrast, the PN+HIIC group still had an elevated L/M ratio until POD+12. The ratios of L/M in the EN+HIIC group on POD+7 and POD+12 were significantly different from those of the PN+HIIC group (0.0855 ± 0.0462 vs 0.1298 ± 0.063, <italic>P</italic> = .007; 0.0336 ± 0.0235 vs 0.0616 ± 0.0430, <italic>P</italic> = .038, respectively). <italic>Conclusion</italic>: Gastric cancer radical resection resulted in a significant increase in intestinal permeability. HIIC aggravated the injury of intestinal mucous permeability, which could be reversed by EN.</p>
</abstract>
<kwd-group>
<kwd>enteral nutrition</kwd>
<kwd>parenteral nutrition</kwd>
<kwd>oncology</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607111414022">
<title>Clinical Relevancy Statement</title>
<p>Our study found that compared with treatment using systemic chemotherapy, hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) injures the intestinal mucosal permeability of advanced gastric cancer patients. The increased permeability of the gut is associated with postsurgical infectious complications. After gastric radical resection, enteral nutrition (EN) supplementation could extenuate the increased permeability of intestinal mucous induced by HIIC and promote postoperative recovery in patients.</p>
</sec>
<sec id="section2-0148607111414022">
<title>Background</title>
<p>Gastric cancer is the second-leading cause of cancer-related mortality worldwide, especially in East Asia.<sup><xref ref-type="bibr" rid="bibr1-0148607111414022">1</xref></sup> The poor prognosis of gastric cancer after radical resection is mainly caused by peritoneal metastasis, which is related to 50% recurrence of gastric cancer,<sup><xref ref-type="bibr" rid="bibr2-0148607111414022">2</xref></sup> and systemic chemotherapy is mostly ineffective for these cases.<sup><xref ref-type="bibr" rid="bibr3-0148607111414022">3</xref></sup> The results from randomized controlled trials demonstrate that intraperitoneal chemotherapy, especially HIIC or HIIC combined with early postoperative intraperitoneal chemotherapy, potentially play a role in improvement of overall survival of patients with advanced gastric cancer; however, intraperitoneal chemotherapy is also associated with an increase risk of intra-abdominal abscess.<sup><xref ref-type="bibr" rid="bibr4-0148607111414022">4</xref></sup></p>
<p>The complication of infection is related to chemotherapy-induced leukopenia and mucosal barrier function damage in malignant tumor patients. Clinical investigators found that chemotherapy increases the intestinal mucosal permeability of patients with gastrointestinal cancer.<sup><xref ref-type="bibr" rid="bibr5-0148607111414022">5</xref></sup> Meanwhile, in animal studies, Song and colleagues confirmed that intraperitoneal injection with 5-fluorouracil or methotrexate, both of which are widely used in intraperitoneal chemotherapy, can injure the intestinal barrier function, increase the intestinal permeability, and result in the bacterial translocation.<sup><xref ref-type="bibr" rid="bibr6-0148607111414022">6</xref>,<xref ref-type="bibr" rid="bibr7-0148607111414022">7</xref></sup> However, few clinical studies investigated the relationship between intraoperative intraperitoneal chemotherapy and the intestinal mucosal injury.</p>
<p>It is well known that gastrointestinal surgery, such as gastric radical resection, can injury the intestine mucosal barrier.<sup><xref ref-type="bibr" rid="bibr8-0148607111414022">8</xref></sup> Compared with total parenteral nutrition (PN) after surgery, early EN can reverse the injury of the mucosal barrier.<sup><xref ref-type="bibr" rid="bibr8-0148607111414022">8</xref></sup> The purpose of this study was to assess the injury effect of HIIC on intestinal mucosa and the protection of early postoperative EN in locally advanced gastric cancer patients after radical surgery.</p>
</sec>
<sec id="section3-0148607111414022" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section4-0148607111414022">
<title>Patients</title>
<p>Sixty-five patients with locally advanced gastric cancer treated with intraoperative intraperitoneal chemotherapy were enrolled with signed informed consent from December 2007 to December 2008 in Jiangsu Cancer Hospital. All patients were diagnosed with muscularis propria invasion ≥ T2, without invasion of adjacent structures (TNM staging per the sixth edition of the American Joint Committee on Cancer) and without distant metastasis, confirmed by endoscopic ultrasonography and intraoperative examination. All patients had a Karnofsky performance status no worse than 80 (a subjective measure of how well the patient is doing). The patients were randomized intraoperatively into 3 groups according to a randomization table prepared by the Fresenius Medical Department using randomization software (NDTS statistic software, approved by the Drug Administration Bureau). Per the inclusion criteria, patients received an ascending serial number in the order of their enrollment and were assigned to one of the three groups based on their number. This study was conducted according to the principles of the Declaration of Helsinki/Hong Kong of 1989, and the good clinical practice guidelines of the European Community, the United States, and China. The protocol and informed consent were approved by the Ethics Committee of Jiangsu Cancer Hospital.</p>
<p>Treatment groups were as follows.</p>
<list id="list1-0148607111414022" list-type="simple">
<list-item><p><italic>EN group</italic>: Patients (n = 22) were randomized to be fed. These patients received EN via jejunostomy tube, which was placed approximately 20 cm distal to the ligament of Treitz or 20 cm distal to the site of gastrojejunostomy, starting on postoperative day 3 (POD+3).</p></list-item>
<list-item><p><italic>EN+HIIC group</italic>: Patients (n = 23) were treated with HIIC and EN support until postoperative day 9 (POD+9).</p></list-item>
<list-item><p><italic>PN+HIIC group</italic>: Patients (n = 20) were treated with HIIC and PN via central venous catheter from POD+3.</p></list-item>
</list>
</sec>
<sec id="section5-0148607111414022">
<title>Intraoperative Intraperitoneal Chemotherapy</title>
<p>All patients underwent R0 gastric resection with greater and lesser omentectomy, with or without splenectomy, and D2 lymph node dissection. At the end of the operation, 2 drains were inserted in the peritoneal cavity. Before closure of the patients’ abdomens in the EN+HIIC and PN+HIIC groups, a bolus was administered in the peritoneal cavity—a perfusate solution consisting of floxuridine (FUdR; 1000 mg/m<sup>2</sup>) plus leucovorin<sup><xref ref-type="bibr" rid="bibr9-0148607111414022">9</xref></sup> (240 mg/m<sup>2</sup>) and cisplatin<sup><xref ref-type="bibr" rid="bibr10-0148607111414022">10</xref></sup> (40 mg/m<sup>2</sup>) mixed in normal saline ranging from 40°C to 42°C—which remained for 4 hours and was then drained. The volume of the intraperitoneal chemotherapy solution was adjusted to patients’ body surface areas: 1 L for patients with a body surface area ≤ 1.5m<sup>2</sup> and 2 L for patients with a body surface area &gt; 1.5m<sup>2</sup>. No drugs were placed in the peritoneal cavity of the patients in the EN group.</p>
</sec>
<sec id="section6-0148607111414022">
<title>Nutrition</title>
<p>The 3 groups received isonitrogenous nutrition support (0.2 g/kg/d) and isocaloric nutrition support (nonprotein calories: 30 kcal/kg/d or calculated as Harris-Benedict formula) from POD+3 to POD+9 (7 days). The goal of EN or PN was to provide 50% of nutritional requirements on POD+3, 75% on POD+4, and 100% on POD+5. The ratio of glucose calories to fat calories was 1:1; the ratio of nitrogen to nonprotein kilocalories was 1:150. The Harris-Benedict formula is as follows: basal energy expenditure (male) = 66.47 + 13.75(body weight, kg) + 5.0033(height, cm) – 6.755(age, years); basal energy expenditure (female) = 65.51 + 9.563(body weight, kg) + 1.85(height, cm) – 4.676(age, years).</p>
<p>For the EN group and the EN+HIIC group, patients received EN suspension (Nutrison Fibre, Nutricia Corp, China) containing 20 g of protein, 19.5 g of fat, 61.5 g of carbohydrate calories, 7.5 g of fiber, 2.5 g of minerals, and 150 mg of vitamins per 500 mL. Nutrient solution was given at a low speed, which was increased gradually to 100 to 120 mL/h. For the PN+IIC group, patients received PN. Amino acids, fat, glucose, and minerals were mixed in an all-in-one bag and infused steadily. Patients’ diets were not restricted after surgery.</p>
</sec>
<sec id="section7-0148607111414022">
<title>Lactulose/Mannitol Ratio</title>
<p>The intestinal permeability detection was performed on POD-1, POD+3, POD+7, and POD +12. All patients fasted at least 6 hours, and their bladders were emptied before oral administration of the test. They resumed drinking at least 2 hours and eating at lease 6 hours since the test began. The test solution consisted of 10 g of lactulose and 5 g of mannitol in a total volume of 50 mL (Sigma, U.S.). The solution was given as a bolus via the nasoenteric tube or by oral routes. Nasogastric tubes were clamped for 6 hours after administration of the test solution. The total urine volume was collected for the subsequent 6 hours. The urine volume was recorded, and an aliquot was frozen and stored at −80°C. We calculated intestinal permeability using the lactulose/mannitol ratio (L/M): 6-hour excretion rate of lactulose in the urine / 6-hour excretion rate of mannitol in the urine. Urinary lactulose and mannitol were assayed using high-pressure liquid chromatography as described.<sup><xref ref-type="bibr" rid="bibr11-0148607111414022">11</xref></sup> The analyses were performed in the laboratory of the Research Institute of General Surgery, Jingling Hospital, Nanjing, Jiangsu Province, China.</p>
</sec>
<sec id="section8-0148607111414022">
<title>Statistics</title>
<p>All data are expressed as means ± SEM. Statistical analysis was performed using analysis of variance when comparing mean L/M ratios within groups and by an independent <italic>t</italic> test for differences among groups; enumeration data were analyzed by χ<sup>2</sup> test. Significant values &lt; .05 were considered. All statistical calculations were performed using SPSS 15.0 for Windows.</p>
</sec>
</sec>
<sec id="section9-0148607111414022" sec-type="results">
<title>Results</title>
<sec id="section10-0148607111414022">
<title>Patients General Data and Safety</title>
<p>From December 2007 to December 2008, 65 patients with locally advanced gastric cancer were enrolled and randomly divided into 3 groups, which received early postoperative EN or total parental nutrition with or without HIIC. All diagnoses of gastric cancer were based on final pathology. Preoperative data of patients were similar among the 3 groups, as listed in <xref ref-type="table" rid="table1-0148607111414022">Table 1</xref>.</p>
<table-wrap id="table1-0148607111414022" position="float">
<label>Table 1.</label>
<caption><p>Characteristics of Patients (N = 65)</p></caption>
<graphic alternate-form-of="table1-0148607111414022" xlink:href="10.1177_0148607111414022-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">EN</th>
<th align="center">EN+HIIC</th>
<th align="center">PN+HIIC</th>
<th align="center"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, n</td>
<td>22</td>
<td>23</td>
<td>20</td>
<td align="center">—</td>
</tr>
<tr>
<td>Age,<sup>a</sup> y</td>
<td>57.2 ± 6.9</td>
<td>55.3 ± 10.1</td>
<td>57.6 ± 8.4</td>
<td>&gt; .05</td>
</tr>
<tr>
<td>Karnofsky performance scores<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414022">a</xref></sup></td>
<td>93.6 ± 7.3</td>
<td>90.4 ± 8.8</td>
<td>93.5 ± 5.9</td>
<td>&gt; .05</td>
</tr>
<tr>
<td>Sex: male, female</td>
<td>16, 6</td>
<td>18, 5</td>
<td>14, 6</td>
<td>.819</td>
</tr>
<tr>
<td>Anatomic location: upper, middle, low</td>
<td>4, 6, 12</td>
<td>6, 6, 11</td>
<td>4, 6, 10</td>
<td>.971</td>
</tr>
<tr>
<td>Depth of tumor invasion: pT2, pT3, pT4</td>
<td>4, 14, 4</td>
<td>7, 13, 3</td>
<td>3, 16, 1</td>
<td>.437</td>
</tr>
<tr>
<td>Lymph node metastasis: pN0, pN1,2,3</td>
<td>5, 17</td>
<td>5, 18</td>
<td>3, 17</td>
<td>.795</td>
</tr>
<tr>
<td>Borrmann type: II, III, IV</td>
<td>5, 15, 2</td>
<td>7, 13, 3</td>
<td>6, 13, 1</td>
<td>.860</td>
</tr>
<tr>
<td>Gastrectomy: total, subtotal (proximal or distal)</td>
<td>7, 15</td>
<td>9, 14</td>
<td>10, 10</td>
<td>.483</td>
</tr>
<tr>
<td colspan="5">Body weight,<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414022">a</xref></sup> kg</td>
</tr>
<tr>
<td> POD-1</td>
<td>65.1 ± 10.6</td>
<td>71.4 ± 11.4</td>
<td>67.7 ± 11.4</td>
<td>.174</td>
</tr>
<tr>
<td> POD+12</td>
<td>62.2 ± 10.5</td>
<td>66.3 ± 10.6</td>
<td>61.2 ± 10.2</td>
<td>.238,<sup><xref ref-type="table-fn" rid="table-fn3-0148607111414022">b</xref></sup> .935,<sup><xref ref-type="table-fn" rid="table-fn4-0148607111414022">c</xref></sup> .667,<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414022">d</xref></sup> .597<sup><xref ref-type="table-fn" rid="table-fn6-0148607111414022">e</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607111414022">
<p>EN, enteral nutrition; HIIC, hyperthermic intraoperative intraperitoneal chemotherapy; PN, parenteral nutrition; POD-1, 1 day before operation; POD+12, 12 days after operation.</p>
</fn>
<fn id="table-fn2-0148607111414022">
<label>a</label>
<p>Values presented as mean ± SD.</p>
</fn>
<fn id="table-fn3-0148607111414022">
<label>b</label>
<p>Among EN group, EN+HIIC group, and PN+HIIC group.</p>
</fn>
<fn id="table-fn4-0148607111414022">
<label>c</label>
<p>Between POD-1 and POD+12 in EN group.</p>
</fn>
<fn id="table-fn5-0148607111414022">
<label>d</label>
<p>Between POD-1 and POD+12 in EN+HIIC group.</p>
</fn>
<fn id="table-fn6-0148607111414022">
<label>e</label>
<p>Between POD-1 and POD+12 in PN+HIIC group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The results show that all the clinical laboratory parameters of safety were similar among the groups (<xref ref-type="table" rid="table2-0148607111414022">Table 2</xref>), except the serum level of albumin, of which the Δ in the EN or EN+HIIC group was significantly higher than that in the PN+HIIC group. All patients were well tolerant with the L/M test and the EN or PN treatment. During the postoperative period, no operative complications were observed (anastomotic leakage, abdominal abscess, pancreatitis, pneumonia, intestinal obstruction, et al), and no chemotherapy toxicity reactions were observed (eg, anemia, leucopenia, renal toxicity, neuropathy, and chemical peritonitis). <xref ref-type="table" rid="table2-0148607111414022">Table 2</xref> displays the clinical biochemistry comparison of the 3 groups before and after the operation.</p>
<table-wrap id="table2-0148607111414022" position="float">
<label>Table 2.</label>
<caption><p>Clinical Laboratory and Clinical Chemistry Laboratory Parameters<sup><xref ref-type="table-fn" rid="table-fn8-0148607111414022">a</xref></sup></p></caption>
<graphic alternate-form-of="table2-0148607111414022" xlink:href="10.1177_0148607111414022-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter: Group</th>
<th align="center">POD-1</th>
<th align="center">POD+12</th>
<th align="center">Δ (POD+12 – POD-1)</th>
<th align="center"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">White blood cells, 10<sup>9</sup>/L</td>
</tr>
<tr>
<td> EN</td>
<td>5.94 ± 1.23</td>
<td>6.6 ± 1.4</td>
<td>0.65 ± 1.83</td>
<td>.181</td>
</tr>
<tr>
<td> EN+HIIC</td>
<td>6.00 ± 1.64</td>
<td>7.0 ± 1.37</td>
<td>0.887 ± 1.99</td>
<td/>
</tr>
<tr>
<td> PN+HIIC</td>
<td>5.29 ± 1.15</td>
<td>6.83 ± 1.4</td>
<td>1.64 ± 1.42</td>
<td/>
</tr>
<tr>
<td colspan="5">Alanine aminotransferase, IU/L</td>
</tr>
<tr>
<td> EN</td>
<td>25.4 ± 15.9</td>
<td>28.36 ± 11.48</td>
<td>2.95 ± 18.79</td>
<td>.681</td>
</tr>
<tr>
<td> EN+HIIC</td>
<td>28.7 ± 16.4</td>
<td>34.83 ± 21.56</td>
<td>5.52 ± 24.65</td>
<td/>
</tr>
<tr>
<td> PN+HIIC</td>
<td>21.4 ± 12.2</td>
<td>30.0 ± 18.18</td>
<td>9.1 ± 24.12</td>
<td/>
</tr>
<tr>
<td colspan="5">Blood urea nitrogen, mmol/L</td>
</tr>
<tr>
<td> EN</td>
<td>7.5 ± 4.2</td>
<td>8.0 ± 3.6</td>
<td>0.5 ± 6.1</td>
<td>.959</td>
</tr>
<tr>
<td> EN+HIIC</td>
<td>6.1 ± 2.1</td>
<td>6.5 ± 3.3</td>
<td>0.4 ± 3.2</td>
<td/>
</tr>
<tr>
<td> PN+HIIC</td>
<td>5.9 ± 3.3</td>
<td>6.7 ± 1.8</td>
<td>0.8 ± 3.7</td>
<td/>
</tr>
<tr>
<td colspan="5">Serum creatine, µmol/L</td>
</tr>
<tr>
<td> EN</td>
<td>70.1 ± 21.2</td>
<td>65.8 ± 15</td>
<td>−4.3 ± 21.8</td>
<td>.867</td>
</tr>
<tr>
<td> EN+HIIC</td>
<td>82.2 ± 25.6</td>
<td>77.3 ± 18.6</td>
<td>−4.9 ± 31.4</td>
<td/>
</tr>
<tr>
<td> PN+HIIC</td>
<td>82.2 ± 17.2</td>
<td>70.3 ± 28</td>
<td>−8.4 ± 25.9</td>
<td/>
</tr>
<tr>
<td colspan="5">Total protein, g/L</td>
</tr>
<tr>
<td> EN</td>
<td>67.8 ± 16.9</td>
<td>69.5 ± 13.5</td>
<td>1.4 ± 21.8</td>
<td>.55</td>
</tr>
<tr>
<td> EN+HIIC</td>
<td>70.5 ± 10.3</td>
<td>65.9 ± 7.8</td>
<td>−4.6 ± 13.4</td>
<td/>
</tr>
<tr>
<td> PN+HIIC</td>
<td>66.7 ± 12.5</td>
<td>62.8 ± 14.4</td>
<td>−1.5 ± 18.3</td>
<td/>
</tr>
<tr>
<td colspan="5">Albumin,<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414022">b</xref></sup> g/L</td>
</tr>
<tr>
<td> EN</td>
<td>41.3 ± 7.6</td>
<td>40.27 ± 6.9</td>
<td>−1.5 ± 6.3</td>
<td>.001</td>
</tr>
<tr>
<td> EN+HIIC</td>
<td>39.6 ± 5.3</td>
<td>35.0 ± 5.2</td>
<td>−4.6 ± 6.3</td>
<td/>
</tr>
<tr>
<td> PN+HIIC</td>
<td>41.5 ± 4.2</td>
<td>33.1 ± 4.3</td>
<td>−8.3 ± 4.0</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0148607111414022">
<p>POD-1, 1 day before operation; POD+12, 12 days after operation; EN, enteral nutrition; HIIC, hyperthermic intraoperative intraperitoneal chemotherapy; PN, parenteral nutrition.</p>
</fn>
<fn id="table-fn8-0148607111414022">
<label>a</label>
<p>N = 65; EN group, n = 22; EN+HIIC group, n = 23; EN+HIIC group vs EN group : PN+HIIC group, n = 20. Values presented as mean ± SD.</p>
</fn>
<fn id="table-fn9-0148607111414022">
<label>b</label>
<p>EN vs EN+HIIC, <italic>P</italic> = .068; EN vs PN+HIIC, <italic>P</italic> &lt; .0001; EN+HIIC vs PN+HIIC, <italic>P</italic> = .038.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0148607111414022">
<title>Intestinal Permeability</title>
<p>Urine L/M ratio expressed the intestinal permeability in patients. <xref ref-type="fig" rid="fig1-0148607111414022">Figure 1</xref> depicts the mean L/M ratios for all groups. On POD-1, we found no significant differences among the groups: EN+HIIC (0.0305 ± 0.0208), PN+HIIC (0.0298 ± 0.0229), and EN (0.0280 ± 0.0183) (<italic>P</italic> &gt; .05). Three days after operation, the L/M ratios were increased threefold compared to POD-1 in the 3 groups (EN group: 0.1235 ± 0.0611 vs POD-1, <italic>P</italic> &lt; .0001; EN+HIIC group: 0.1648 ± 0.0571 vs POD-1, <italic>P</italic> &lt; .0001; PN+HIIC group: 0.1702 ± 0.0628 vs POD-1, <italic>P</italic> &lt; .0001), and then a decreasing of the L/M ratio was found after POD+3. Except the ratio of the patients in the PN+HIIC group (POD+12: 0.0616 ± 0.0430 vs POD-1: 0.0298 ± 0.0229, <italic>P</italic> = .032), the L/M ratios recovered on POD +12 (EN group: 0.0278 ± 0.0217 vs POD-1, <italic>P</italic> = 1.000; EN+HIIC group: 0.0336 ± 0.0235 vs POD-1, <italic>P</italic> = .965).</p>
<fig id="fig1-0148607111414022" position="float">
<label>Figure 1.</label>
<caption><p>Lactulose/mannitol ratio comparison among 3 groups. Values are presented as mean ± SD. N = 65; EN group, n = 22; EN+HIIC group, n = 23; PN+HIIC group, n = 20. EN, enteral nutrition; HIIC, hyperthermic intraoperative intraperitoneal chemotherapy; PN, parenteral nutrition; POD-1, 1 day before operation; POD+3, 3 days after operation; POD+7, 7 days after operation; POD+12, 12 days after operation.</p></caption>
<graphic xlink:href="10.1177_0148607111414022-fig1.tif"/>
</fig>
<p>On POD+3, we found significant differences of the L/M ratio between EN+HIIC group, PN+HIIC group and EN group (EN+HIIC group vs EN group: <italic>P</italic> = .025 and PN+HIIC group vs EN group: <italic>P</italic> = .015, respectively). On POD+7, the difference of L/M ratios between the EN+HIIC group and the PN+HIIC group was significant (<italic>P</italic> = .007). Although the L/M ratio on POD+12 in the PN+HIIC group was recovered, we observed differences between the EN group, the EN+HIIC group and PN+HIIC group (EN group vs PN+HIIC group: <italic>P</italic> = .010 and EN+HIIC group vs PN+HIIC group: <italic>P</italic> = .038, respectively).</p>
</sec>
</sec>
<sec id="section12-0148607111414022" sec-type="discussion">
<title>Discussion</title>
<p>Surgical resection is the main treatment for advanced gastric cancer. After radical gastrectomy and D2 lymph node dissection, with or without adjuvant systemic chemotherapy or radiotherapy, the long-term survival of patients with advanced gastric cancer remains limited. Cancer cell dissemination within the peritoneal cavity was an important factor of treatment failure. HIIC is applied to eliminate the residual tumor cells, especially for stage 3 and 4 gastric adenocarcinoma. A meta-analysis confirmed that HIIC with or without early postoperative intraperitoneal chemotherapy after resection of advanced gastric cancer could improve overall survival.<sup><xref ref-type="bibr" rid="bibr4-0148607111414022">4</xref></sup></p>
<p>The drugs used widely in intraperitoneal chemotherapy are mitomycin, 5-fluorouracil, and cisplatin. FUdR is a fluoropyrimidine derivative and is almost entirely extracted on its first pass through the liver,<sup><xref ref-type="bibr" rid="bibr12-0148607111414022">12</xref></sup> which can be considered a more direct precursor of fluorodeoxyuridylate monophosphate than 5-fluorouracil. The cytotoxicity to cancer cell lines occurs at nanomolar ranges even after exposures &lt; 24 hours. With good tolerance and effect,<sup><xref ref-type="bibr" rid="bibr9-0148607111414022">9</xref></sup> FUdR is an ideal candidate for intraperitoneal administration.<sup><xref ref-type="bibr" rid="bibr13-0148607111414022">13</xref></sup> However, investigators found that, compared with bolus intraperitoneal administration, continuous intraperitoneal infusion of FUdR had the higher toxicity and equal efficacy and might be not suitable for treatment of gastric cancer.<sup><xref ref-type="bibr" rid="bibr14-0148607111414022">14</xref></sup> Moreover, a 24-hour continuous infusion schedule with a low dosage of FUdR had similar toxicity compared with bolus administration of high-dose FUdR.<sup><xref ref-type="bibr" rid="bibr15-0148607111414022">15</xref></sup> Thus, we treated patients with bolus intraperitoneal infusion of FUdR. After operation and HIIC and unlike other studies with many complications, in our study no patients had anastomotic leakage, abdominal abscess, pancreatitis, pneumonia, intestinal obstruction, chemical peritonitis, server hematologic toxicity, and gastrointestinal complications. Thus, the treatment performed herein is considered generally well tolerated and suitable for intraperitoneal infusion.</p>
<p>Compared with surgery alone, intraperitoneal chemotherapy increased the risk of intra-abdominal abscess.<sup><xref ref-type="bibr" rid="bibr4-0148607111414022">4</xref></sup> Clinical investigators believe that the impaired barrier function of intestinal mucosa plays a central role in the pathophysiology of systemic infection, shock, and sepsis syndrome.<sup><xref ref-type="bibr" rid="bibr16-0148607111414022">16</xref></sup> The intra-abdominal abscess could be associated with injury of the mucosal barrier, and the intestinal mucosal barrier dysfunction manifested as the increased permeability of intestinal mucosa. In other words, an increased intestinal permeability indicates decreased intestinal barrier function. The L/M ratio is a reliable and sensitive marker of intestinal mucosal permeability shortly after injury<sup><xref ref-type="bibr" rid="bibr17-0148607111414022">17</xref>,<xref ref-type="bibr" rid="bibr18-0148607111414022">18</xref></sup> and is widely used. Investigators reported that the mucosal permeability of patients with digestive tract malignant tumors was significantly higher than that of healthy volunteers.<sup><xref ref-type="bibr" rid="bibr19-0148607111414022">19</xref></sup> The outcome of our study was similar with their results, and we also found that the L/M ratios of all patients were significantly increased after gastrectomy.</p>
<p>Animal and clinical studies proved that systemic chemotherapy can increase the permeability of mucosa in malignant tumor patients.<sup><xref ref-type="bibr" rid="bibr20-0148607111414022">20</xref>,<xref ref-type="bibr" rid="bibr21-0148607111414022">21</xref></sup> In addition, few data indicate whether HIIC is associated with the injury of mucosal permeability. Our study found that a significant difference of L/M ratios existed between the EN group and the EN+HIIC group, and between the EN group and the PN+HIIC group on POD+3, suggesting that HIIC can aggravate the injury of mucosal permeability after gastric resection. In addition, the slow recovery of mucosal injury was observed during the postoperative period. We found that on POD+12, the L/M ratio declined to the baseline in groups except the PN+HIIC group. Clinical study proved that EN can improve the injury of intestinal mucous permeability more effectively than PN after an early operative period.<sup><xref ref-type="bibr" rid="bibr8-0148607111414022">8</xref></sup> Compared with that of the EN+HIIC group on POD+3, POD+7, and POD+12, the recovery of the permeability in the PN+HIIC group was slower. In addition, the Δ of serum levels of albumin between POD-1 and POD+12 in the EN+HIIC group and the PN+HIIC group was significantly different (–4.6 ± 6.3 vs –8.3 ± 4.0, <italic>P</italic> = .038). The effect of EN on mucosal permeability was better than that of PN after HIIC and gastric cancer radical resection.</p>
<p>Intraoperative peritoneal chemotherapy produced a high locoregional concentration of the chemotherapeutic drug delivered to the abdominal cavity, which was greater than that delivered systemically and which avoided unnecessary systemic toxicity. It was proved that hyperthermia could strength the effect of intraoperative peritoneal chemotherapy because of its potential direct cytotoxic effect on heat and synergism. Hyperthermia has a well-established selective and lethal effect on neoplastic tissue, both in vitro and in vivo. Synergistic cytotoxicity has been demonstrated when hyperthermia is combined with several chemotherapeutic agents, including cisplatin.<sup><xref ref-type="bibr" rid="bibr22-0148607111414022">22</xref>,<xref ref-type="bibr" rid="bibr23-0148607111414022">23</xref></sup> Some investigators proved that the hyperthermia stress could induce the increase of the intestinal permeability in rats.<sup><xref ref-type="bibr" rid="bibr24-0148607111414022">24</xref>,<xref ref-type="bibr" rid="bibr25-0148607111414022">25</xref></sup> Therefore, we considered that the synergistic effects of hyperthermia and chemotherapeutic agents could lead to the increase of intestinal permeability in our study.</p>
<p>In conclusion, the intestinal mucosal permeability of patients with gastric cancer increases after operation, and HIIC can aggravate the injury of mucosal permeability. EN during the early operative period can improve permeability more effectively than PN.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: This work was supported by the the natural science foundation of Jiangsu Province (No. 2007010), and by the Li jieshou Research Foundation of intestinal mucosal barrier (No. LJS_2009012)</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607111414022">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kelley</surname><given-names>JR</given-names></name>
<name><surname>Duggan</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Gastric cancer epidemiology and risk factors</article-title>. <source>J Clin Epidemiol</source>. <year>2003</year>;<volume>56</volume>:<fpage>1</fpage>-<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr2-0148607111414022">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ajani</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Evolving chemotherapy for advanced gastric cancer</article-title>. <source>Oncologist</source>. <year>2005</year>;<volume>10</volume>:<fpage>49</fpage>-<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr3-0148607111414022">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyerhardt</surname><given-names>JA</given-names></name>
<name><surname>Fuchs</surname><given-names>CS</given-names></name>
</person-group>. <article-title>Adjuvant therapy in gastric cancer: can we prevent recurrences?</article-title> <source>Oncology (Williston Park)</source>. <year>2003</year>;<volume>17</volume>:<fpage>714</fpage>-<lpage>721</lpage>.</citation>
</ref>
<ref id="bibr4-0148607111414022">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yan</surname><given-names>TD</given-names></name>
<name><surname>Black</surname><given-names>D</given-names></name>
<name><surname>Sugarbaker</surname><given-names>PH</given-names></name>
<etal/>
</person-group>. <article-title>A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer</article-title>. <source>Ann Surg Oncol</source>. <year>2007</year>;<volume>14</volume>: <fpage>2702</fpage>-<lpage>2713</lpage>.</citation>
</ref>
<ref id="bibr5-0148607111414022">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Daniele</surname><given-names>B</given-names></name>
<name><surname>Perrone</surname><given-names>F</given-names></name>
<name><surname>Gallo</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomized trial</article-title>. <source>Gut</source>. <year>2001</year>;<volume>48</volume>:<fpage>28</fpage>-<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr6-0148607111414022">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yáñez</surname><given-names>JA</given-names></name>
<name><surname>Teng</surname><given-names>XW</given-names></name>
<name><surname>Roupe</surname><given-names>KA</given-names></name>
<name><surname>Fariss</surname><given-names>MW</given-names></name>
<name><surname>Davies</surname><given-names>NM</given-names></name>
</person-group>. <article-title>Chemotherapy induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase-2</article-title>. <source>J Pharm Pharm Sci</source>. <year>2003</year>;<volume>6</volume>:<fpage>308</fpage>-<lpage>314</lpage>.</citation>
</ref>
<ref id="bibr7-0148607111414022">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname><given-names>D</given-names></name>
<name><surname>Shi</surname><given-names>B</given-names></name>
<name><surname>Xue</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Green fluorescent protein labeling Escherichia coli TG1 confirms intestinal bacterial translocation in a rat model of chemotherapy</article-title>. <source>Curr Microbiol</source>. <year>2006</year>;<volume>52</volume>:<fpage>69</fpage>-<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr8-0148607111414022">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>XH</given-names></name>
<name><surname>Li</surname><given-names>N</given-names></name>
<name><surname>Li</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Intestinal permeability in patients after surgical trauma and effect of enteral nutrition versus parenteral nutrition</article-title>. <source>World J Gastroenterol</source>. <year>2003</year>;<volume>9</volume>:<fpage>1878</fpage>-<lpage>1880</lpage>.</citation>
</ref>
<ref id="bibr9-0148607111414022">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brenner</surname><given-names>B</given-names></name>
<name><surname>Shah</surname><given-names>MA</given-names></name>
<name><surname>Karpeh</surname><given-names>MS</given-names></name>
<etal/>
</person-group>. <article-title>A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine leucovorin in patients with locally advanced gastric cancer</article-title>. <source>Ann Oncol</source>. <year>2006</year>;<volume>17</volume>:<fpage>1404</fpage>-<lpage>1411</lpage>.</citation>
</ref>
<ref id="bibr10-0148607111414022">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noh</surname><given-names>SH</given-names></name>
<name><surname>Yoo</surname><given-names>CH</given-names></name>
<name><surname>Chung</surname><given-names>HC</given-names></name>
<name><surname>Roh</surname><given-names>JK</given-names></name>
<name><surname>Shin</surname><given-names>DW</given-names></name>
<name><surname>Min</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer</article-title>. <source>Oncology</source>. <year>2001</year>;<volume>60</volume>:<fpage>24</fpage>-<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr11-0148607111414022">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willems</surname><given-names>D</given-names></name>
<name><surname>Cadranel</surname><given-names>S</given-names></name>
<name><surname>Jacobs</surname><given-names>W</given-names></name>
</person-group>. <article-title>Measurement of urinary sugars by HPLC in the estimation of intestinal permeability: evaluation in pediatric clinical practice</article-title>. <source>Clin Chem</source>. <year>1993</year>;<volume>39</volume>:<fpage>888</fpage>-<lpage>890</lpage>.</citation>
</ref>
<ref id="bibr12-0148607111414022">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ensminger</surname><given-names>WD</given-names></name>
<name><surname>Rosowsky</surname><given-names>A</given-names></name>
<name><surname>Raso</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>A clinical-pharmaco-logical evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil</article-title>. <source>Cancer Res</source>. <year>1978</year>;<volume>38</volume>:<fpage>3784</fpage>-<lpage>3792</lpage>.</citation>
</ref>
<ref id="bibr13-0148607111414022">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kelsen</surname><given-names>DP</given-names></name>
<name><surname>Saltz</surname><given-names>L</given-names></name>
<name><surname>Cohen</surname><given-names>AM</given-names></name>
<etal/>
</person-group>. <article-title>A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer</article-title>. <source>Cancer</source>. <year>1994</year>;<volume>74</volume>:<fpage>2224</fpage>-<lpage>2233</lpage>.</citation>
</ref>
<ref id="bibr14-0148607111414022">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>K</given-names></name>
<name><surname>Onishi</surname><given-names>H</given-names></name>
<name><surname>Kato</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of intraperitoneal continuous infusion of floxuridine and bolus administration in a peritoneal gastric cancer xenograft model</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2004</year>;<volume>53</volume>:<fpage>415</fpage>-<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr15-0148607111414022">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sullivan</surname><given-names>RD</given-names></name>
<name><surname>Miller</surname><given-names>E</given-names></name>
</person-group>. <article-title>The clinical effects of prolonged intravenous infusion of 5-fluoro-2′-deoxyuridine</article-title>. <source>Cancer Res</source>. <year>1965</year>;<volume>25</volume>:<fpage>1025</fpage>-<lpage>1033</lpage>.</citation>
</ref>
<ref id="bibr16-0148607111414022">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De-Souza</surname><given-names>DA</given-names></name>
<name><surname>Greene</surname><given-names>LJ</given-names></name>
</person-group>. <article-title>Intestinal permeability and systemic infections in critically ill patients: effect of glutamine</article-title>. <source>Crit Care Med</source>. <year>2005</year>;<volume>33</volume>:<fpage>1125</fpage>-<lpage>1135</lpage>.</citation>
</ref>
<ref id="bibr17-0148607111414022">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trvis</surname><given-names>S</given-names></name>
<name><surname>Menzies</surname><given-names>I</given-names></name>
</person-group>. <article-title>Intestinal permeability: functional assessment and significance</article-title>. <source>Clin Sci (Lond)</source>. <year>1992</year>;<volume>82</volume>:<fpage>471</fpage>-<lpage>488</lpage>.</citation>
</ref>
<ref id="bibr18-0148607111414022">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edwin</surname><given-names>A</given-names></name>
<name><surname>Deitch</surname><given-names>S</given-names></name>
</person-group>. <article-title>Intestinal permeability increased in burn patients shortly after injury</article-title>. <source>Surgery</source>. <year>1990</year>;<volume>107</volume>:<fpage>411</fpage>-<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr19-0148607111414022">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yao</surname><given-names>YC</given-names></name>
<name><surname>Chen</surname><given-names>CL</given-names></name>
<name><surname>Wang</surname><given-names>JD</given-names></name>
<name><surname>Zhang</surname><given-names>YL</given-names></name>
<name><surname>Jiang</surname><given-names>B</given-names></name>
<name><surname>Xiong</surname><given-names>DX</given-names></name>
</person-group>. <article-title>Intestinal permeability of patients with advanced digestive tract malignant tumors</article-title>. <source>Di Yi Jun Yi Da Xue Xue Bao</source>. <year>2004</year>;<volume>24</volume>:<fpage>569</fpage>-<lpage>571</lpage>.</citation>
</ref>
<ref id="bibr20-0148607111414022">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kohout</surname><given-names>P</given-names></name>
<name><surname>Cerman</surname><given-names>J</given-names></name>
<name><surname>Brátová</surname><given-names>M</given-names></name>
<name><surname>Zadák</surname><given-names>Z</given-names></name>
</person-group>. <article-title>Small-bowel permeability in patients with cytostatic therapy</article-title>. <source>Nutrition</source>. <year>1999</year>;<volume>15</volume>:<fpage>546</fpage>-<lpage>549</lpage>.</citation>
</ref>
<ref id="bibr21-0148607111414022">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Yu</surname><given-names>Z</given-names></name>
<name><surname>Liu</surname><given-names>F</given-names></name>
<name><surname>Tan</surname><given-names>L</given-names></name>
<name><surname>Wu</surname><given-names>B</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
</person-group>. <article-title>Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: a prospective randomized trial</article-title>. <source>Tumori</source>. <year>2006</year>;<volume>92</volume>:<fpage>396</fpage>-<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr22-0148607111414022">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>RC</given-names></name>
<name><surname>Richards</surname><given-names>M</given-names></name>
<name><surname>Baird</surname><given-names>C</given-names></name>
<name><surname>Hall</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>Interaction of hyperthermia and chemotherapy agents: cell lethality and oncogenic potential</article-title>. <source>Int J Hyperthermia</source>. <year>1994</year>;<volume>10</volume>:<fpage>89</fpage>-<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr23-0148607111414022">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hildebrandt</surname><given-names>B</given-names></name>
<name><surname>Wust</surname><given-names>P</given-names></name>
<name><surname>Ahlers</surname><given-names>O</given-names></name>
<etal/>
</person-group>. <article-title>The cellular and molecular basis of hyperthermia</article-title>. <source>Crit Rev Oncol-Hematol</source>. <year>2002</year>;<volume>43</volume>:<fpage>33</fpage>-<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr24-0148607111414022">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lambert</surname><given-names>GP</given-names></name>
<name><surname>Gisolfi</surname><given-names>CV</given-names></name>
<name><surname>Berg</surname><given-names>DJ</given-names></name>
<etal/>
</person-group>. <article-title>Selected contribution: hyperthermia-induced intestinal permeability and the role of oxidative and nitrosative stress</article-title>. <source>J Appl Physiol</source>. <year>2002</year>;<volume>92</volume>:<fpage>1750</fpage>-<lpage>1761</lpage>.</citation>
</ref>
<ref id="bibr25-0148607111414022">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prosser</surname><given-names>C</given-names></name>
<name><surname>Stelwagen</surname><given-names>K</given-names></name>
<name><surname>Cummins</surname><given-names>R</given-names></name>
<name><surname>Guerin</surname><given-names>P</given-names></name>
<name><surname>Gill</surname><given-names>N</given-names></name>
<name><surname>Milne</surname><given-names>C</given-names></name>
</person-group>. <article-title>Reduction in heat-induced gastrointestinal hyperpermeability in rats by bovine colostrum and goat milk powders</article-title>. <source>J Appl Physiol</source>. <year>2004</year>;<volume>96</volume>: <fpage>650</fpage>-<lpage>654</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>